Ron Cohen, Acorda Therapeutics president & CEO

Let­ters to the Ed­i­tor: Don't ex­pect a cor­re­la­tion be­tween an in­di­vid­ual drug's de­vel­op­ment cost and price

End­points News re­cent­ly re­port­ed on a new pa­per in JA­MA that pur­ports to show that there is no cor­re­la­tion be­tween the price of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.